A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

Advanced search
Browse by:

Department | Year

UCL Theses | Latest

Deposit your research

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

Chau, I; Joulain, F; Iqbal, SU; Bridgewater, J; (2014) A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer , 14 , Article 605. 10.1186/1471-2407-14-605. Green open access

Preview	PDF 1471-2407-14-605.pdf Download (1MB)
	Other (ePUB version) 1471-2407-14-605.epub Download (225kB)
	MS Word (Additional file 1: Table S1:) 1471-2407-14-605-s1.doc Download (163kB)

Abstract

The VELOUR study demonstrated a survival benefit for FOLFIRI + aflibercept versus FOLFIRI + placebo in metastatic colorectal cancer (mCRC) patients who progressed on oxaliplatin-based chemotherapy. Continued divergence of overall survival (OS) curves in the intension to treat (ITT) population, with the survival advantage persisting beyond median survival time, suggested subpopulations might have different magnitudes of survival gain. Additionally, 10% of patients within VELOUR had recurrence during or within 6 months of completing oxaliplatin-based adjuvant therapy (adjuvant fast relapsers) - previously identified as having poorer survival outcomes.

Type:	Article
Title:	A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
Open access status:	An open access version is available from UCL Discovery
DOI:	10.1186/1471-2407-14-605
Publisher version:	http://dx.doi.org/10.1186/1471-2407-14-605
Language:	English
Additional information:	© 2014 Chau et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
UCL classification:	UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI:	https://discovery.ucl.ac.uk/id/eprint/1443062